BACKGROUND: Islet cell transplantation (ICT) is a promising approach to cure patients with type 1 diabetes. We have implemented a new immunosuppression protocol with antithymoglobulin plus anti-inflammatory agents of anakinra and eternacept for induction and tacrolimus plus mycophenolate mofetil for maintenance [T-cell depletion with anti-inflammatory (TCD-AI) protocol], resulting in successful single-donor ICT. METHODS: Eight islet recipients with type 1 diabetes reported adverse events (AEs) monthly. AEs were compared between three groups: first infusion with the TCD-AI protocol (TCD-AI-1st) and first and second infusion with the Edmonton-type protocol (Edmonton-1st and Edmonton-2nd). RESULTS: The incidence of symptomatic AEs within the initial three months in the TCD-AI-1st group was less than in the Edmonton-1st and Edmonton-2nd groups, with a marginally significant difference (mean ± SE: 5.5 ± 0.3, 7.5 ± 0.5, and 8.3 ± 1.3, respectively; p = 0.07). A significant reduction in liver enzyme elevation after ICT was found in the TCD-AI-1st group compared with the Edmonton-1st and Edmonton-2nd groups (p < 0.05). Because of AEs, all patients in the Edmonton protocol eventually converted to the TCD-AI protocol, whereas all patients tolerated the TCD-AI protocol. CONCLUSIONS: TCD-AI protocol can be tolerated for successful ICT, although this study includes small cohort, and large population trial should be taken.
BACKGROUND: Islet cell transplantation (ICT) is a promising approach to cure patients with type 1 diabetes. We have implemented a new immunosuppression protocol with antithymoglobulin plus anti-inflammatory agents of anakinra and eternacept for induction and tacrolimus plus mycophenolate mofetil for maintenance [T-cell depletion with anti-inflammatory (TCD-AI) protocol], resulting in successful single-donor ICT. METHODS: Eight islet recipients with type 1 diabetes reported adverse events (AEs) monthly. AEs were compared between three groups: first infusion with the TCD-AI protocol (TCD-AI-1st) and first and second infusion with the Edmonton-type protocol (Edmonton-1st and Edmonton-2nd). RESULTS: The incidence of symptomatic AEs within the initial three months in the TCD-AI-1st group was less than in the Edmonton-1st and Edmonton-2nd groups, with a marginally significant difference (mean ± SE: 5.5 ± 0.3, 7.5 ± 0.5, and 8.3 ± 1.3, respectively; p = 0.07). A significant reduction in liver enzyme elevation after ICT was found in the TCD-AI-1st group compared with the Edmonton-1st and Edmonton-2nd groups (p < 0.05). Because of AEs, all patients in the Edmonton protocol eventually converted to the TCD-AI protocol, whereas all patients tolerated the TCD-AI protocol. CONCLUSIONS:TCD-AI protocol can be tolerated for successful ICT, although this study includes small cohort, and large population trial should be taken.
Authors: A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: S B Cohen; L W Moreland; J J Cush; M W Greenwald; S Block; W J Shergy; P S Hanrahan; M M Kraishi; A Patel; G Sun; M B Bear Journal: Ann Rheum Dis Date: 2004-04-13 Impact factor: 19.103
Authors: Mark C Genovese; Stanley Cohen; Larry Moreland; Deborah Lium; Sean Robbins; Richard Newmark; Pirow Bekker Journal: Arthritis Rheum Date: 2004-05
Authors: Mark S Fineman; Larry Z Shen; Kristin Taylor; Dennis D Kim; Alain D Baron Journal: Diabetes Metab Res Rev Date: 2004 Sep-Oct Impact factor: 4.876
Authors: Yvon Lebranchu; Frank Bridoux; Matthias Büchler; Yannick Le Meur; Isabelle Etienne; Olivier Toupance; Bruno Hurault de Ligny; Guy Touchard; Bruno Moulin; Patrick Le Pogamp; Olivier Reigneau; Michel Guignard; Gérard Rifle Journal: Am J Transplant Date: 2002-01 Impact factor: 8.086
Authors: Aparna K Mohan; Timothy R Coté; Joel A Block; Augustine M Manadan; Jeffrey N Siegel; M Miles Braun Journal: Clin Infect Dis Date: 2004-07-16 Impact factor: 9.079
Authors: Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245
Authors: Hayato Iwase; Hidetaka Hara; Mohamed Ezzelarab; Tao Li; Zhongqiang Zhang; Bingsi Gao; Hong Liu; Cassandra Long; Yi Wang; Amy Cassano; Edwin Klein; Carol Phelps; David Ayares; Abhinav Humar; Martin Wijkstrom; David K C Cooper Journal: Xenotransplantation Date: 2017-03-17 Impact factor: 3.907
Authors: Wen Yuan Chung; Cristina A Pollard; Rohan Kumar; Christopher J Drogemuller; Bashoo Naziruddin; Cordula Stover; Eyad Issa; John Isherwood; Jill Cooke; Marlon F Levy; P Toby H Coates; Giuseppe Garcea; Ashley R Dennison Journal: Ann Transl Med Date: 2021-01